Gallium-transferrin binding in treated and untreated Parkinson's disease

Sarah J. Winsper, Richard A. Armstrong*, Paul S. Hodgkins, John A. Blair

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

The binding of gallium (Ga) to transferrin (Tf) was studied in plasma from control patients, in patients with untreated Parkinson's disease (PD) and in patients with PD treated either with levodopa (L-dopa) alone or in combination with selegiline. Mean percentage Ga-Tf binding was significantly reduced in untreated and treated PD compared with controls. Binding, however, was significantly greater in treated than in untreated patients. There was no difference in binding between patients treated with L-dopa alone and those treated with L-dopa and selegiline. The data support the hypothesis that oxidation reactions may be of pathogenic significance in PD.
Original languageEnglish
Pages (from-to)709-711
Number of pages3
JournalNeuroReport
Volume8
Issue number3
Publication statusPublished - 10 Feb 1997

Keywords

  • gallium-transferrin binding
  • L-dopa
  • oxidation reaction
  • Parkinson's disease
  • selegiline
  • transferrin

Fingerprint Dive into the research topics of 'Gallium-transferrin binding in treated and untreated Parkinson's disease'. Together they form a unique fingerprint.

  • Cite this

    Winsper, S. J., Armstrong, R. A., Hodgkins, P. S., & Blair, J. A. (1997). Gallium-transferrin binding in treated and untreated Parkinson's disease. NeuroReport, 8(3), 709-711.